It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The health data company, based in Bellevue, Washington, plans to collect leftover specimens from consenting patients who get routine health care at participating facilities, Stat reported. Also in the ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...